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OBJECTIVE: The objective of this study was to compare
the McMaster’s Health Utilities Index-Mark III and the
EuroQol-5D in a surgical breast cancer population. 
METHODS: Seventy-five surgical breast cancer patients
participated in the study. The patients were given the
Mark III version of the Health Utilities Index (HUI), and
the EuroQol-5D (EQ) comprising both the classification
system and the thermometer at the same visit, and the or-
der of instrument administration was randomized. Infor-
mation on the age of the patient, the cancer stage, and
the number of comorbidities was obtained through chart
review. 
RESULTS: The mean age of patients was 60 (sd  10.7).
Ninety-six percent of the patients were diagnosed with ei-
ther stage I or II breast cancer. The majority of patients
had up to three comorbid conditions. The mean score on
the HUI was 84.6 (sd  16.8). The mean on the EQ clas-
sification system was 87.4 (sd  13.6), while that on the
EQ thermometer was 86.6 (sd  12.6). The correlation
coefficient between scores on the HUI and the EQ classi-
fication system was 0.54, while that between the HUI
and the EQ thermometer score was 0.66. Eight patients
(10.6%) recorded the highest score on the HUI, 36 patients
(48%) on the EQ classification system, while 12 patients
(16%) indicated “best imaginable health state” on the EQ
thermometer. The EQ classification system classified the
patients into 15 health states, while 33 health states on the
HUI classification system described the sample. 
CONCLUSION: The results of this study show that al-
though both the HUI and the EQ classification systems
are reliable measures of health status, they differ in terms
of instrument sensitivity to disease severity.
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OBJECTIVE: A retrospective claims analysis was per-
formed examining costs of care for breast cancer patients. 
METHODS: Two years of claims data (1/94 to 12/95)
were obtained from a provider of cancer care services to
managed care organizations. Patients with a breast cancer–
related medical claim (ICD-9 code of 174.X) were staged
according to the following criteria. Stage I: lumpectomy,
with no chemotherapy prior to or following lumpectomy,
and no ICD-9 code of 196.X; stage II: ICD-9 code of
196.3; stage III: ICD-9 code of 196.X, but not 196.3; stage
IV: ICD-9 code of 197, 198, or 199. Costs, reflecting the
amount reimbursed by the insurer, were calculated based
on medical and pharmacy resource utilization. Average pe-
riod costs were reported for each stage according to three
time frames: initial (6 months), maintenance (3 months),
and terminal (6 months). 
RESULTS: A total of 1822 female patients had a breast
cancer–related medical claim during this period; 530 pa-
tients were considered evaluable based upon available data.
Stage I patients had the lowest overall costs ($9572), while
stage IV patients experienced the highest overall costs
($34,448). Too few stage III patients (n  19) were identi-
fied to draw conclusions. Overall, highest costs were ob-
served during the terminal period. When data from all pa-
tients were analyzed, per-patient costs were $7183 over an
initial 6-month period, $3901 over a 3-month maintenance
period, and $12,080 over a 6-month terminal period. 
CONCLUSIONS: These results indicate that breast can-
cer patients in this setting utilized substantial medical re-
sources, particularly during the terminal phase of care,
and that utilization, in general, increased with stage.
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OBJECTIVE: The purpose of this study was to review
the HRQoL literature and to determine its usefulness for
assessing the impacts of alternative treatments for pa-
tients with prostate cancer. 
METHODS: A structured search was conducted of
widely available databases to identify studies of HRQoL
applied to prostate cancer, using the following inclusion
criteria: English language literature, original research,
peer-reviewed journal publication, inclusion of 10 or
more patients, and presence of a comparison group.
Manuscripts were analyzed for the type of HRQoL eval-
uated (generic versus disease-specific) prostate cancer–
related health domains analyzed, within- and between-
treatment HRQoL impacts, comparators used, and distri-
bution of studies across cancer stages and treatments. 
RESULTS: Over half (56%) of the 41 HRQoL studies as-
sessed the impact of single-treatment options without re-
gard to other available treatments; 44% compared two
or more therapies. Generic, non-disease-specific instru-
ments detected treatment-related changes in HRQoL in
2/15 (13%) instances. In contrast, 92% (11/12) of the
prostate cancer–specific instrument assessments detected
differences in HRQoL. Four of 14 reported prostate can-










I 228 $4,169 $1,992 $3,411 $9,572
II 87 $6,371 $3,131 $5,176 $14,678
III 19 $637 $557 $7,905 $9,099
IV 196 $12,159 $5,602 $16,687 $34,448
All 530 $7,183 $3,901 $12,080 $23,164
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dated. Overall, 16 (39%) of studies detected a statisti-
cally significant HRQoL difference associated with any
prostate cancer treatment, 6 (37.5%) of which are single-
treatment studies with pre-post designs, 10 (62.5%) of
which are between-treatment studies. 
CONCLUSIONS: Selection of appropriate HRQoL-max-
imizing therapies for prostate cancer patients requires in-
formation on competing alternatives. Currently, the liter-
ature does not adequately address this need. Generic
measures have not been responsive to treatment-related
changes in HRQoL for prostate cancer. More work is
needed to develop sensitive and externally valid measures of
the multiple approaches to treating prostate cancer.
PCD9
UTILIZATION OF COMPLEMENTARY AND 
ALTERNATIVE MEDICINE (CAM) TREATMENTS 
AMONG PROSTATE CANCER PATIENTS
IN CaPSURE
Lubeck DP1, Litwin MS2, Flanders SC3, Henning JM3,
Carroll PR1
1University of California, San Francisco, CA, USA; 2University of 
California Los Angeles, Department of Urology, Los Angeles, 
CA, USA; 3TAP Holdings, Deerfield, IL, USA
OBJECTIVE: Little has been reported on the frequency
of complementary and alternative medicine (CAM) treat-
ments among prostate cancer (PCa) patients despite
growing use in other conditions. This research reports on
utilization of CAM treatments among a group of recently
diagnosed PCa patients. 
METHODS: We identified a cohort of 995 newly diag-
nosed PCa patients enrolled in CaPSURE, a longitudinal
observational database. Patients report on the use of
CAM treatments in quarterly, self-administered question-
naires. Patients indicate whether or not they have used
CAM and then indicate the specific treatment. Chiro-
practic visits are not considered an alternative therapy in
this database. 
RESULTS: Mean age of patients was 75.9 years. Patients
were 71% white and 11% African American, 44% had
some college, median income was $30,000. Median fol-
low-up was 12 months. CAM treatment was reported by
36.4% of patients. The most frequently reported CAM
treatments were: 1) herbal medicine (including Chinese
herbs, other herbs, saw palmetto, and St. John’s Wort),
19.2%; 2) diet, nutrition, and lifestyle modification (such
as smoking cessation or exercise), 9.7%; 3) vitamins/min-
erals, 8.3%; 4) acupuncture, 4.9%; 5) homeopathic reme-
dies, 3.1%; 6) meditation and biofeedback, 1.8%. Other
treatments included: massage/bodywork, immune enhanc-
ers, hypnotherapy, and miscellaneous items such as pet
adoption. 
CONCLUSIONS: We found that a significant proportion
of newly diagnosed PCa patients (36%) reported use of
CAM treatments. These results are similar to data re-
ported for other chronic conditions, such as arthritis,
HIV-infection, and other cancers where 30–60% of pa-
tients report use of CAM therapies. Further research into
the benefit of these therapies in terms of improved pa-
tient functioning is needed.
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Current literature suggests that nearly 18% of lifetime
costs for medical care ($40,000 per person) is estimated
to be incurred in the last year of life and nearly 28% of
US Medicare payments for those over age 65 are for per-
sons in their last year of life (Scitoversusky 1994). Little
has been reported, however, on total medical costs at the
end-of-life for prostate cancer (PCa) patients. 
OBJECTIVE: The aim of this research was to compare
the last year of medical costs in PCa patients dying at
home or in an healthcare institution. 
METHODS: Cost data was extracted on 293 men from
CaPSURE, a longitudinal disease registry of patients with
PCa. Standard charges (1997 dollars) were applied to all
healthcare services in the last four quarters of life. Not all
patients contributed data to each quarter. Descriptive
and multivariate analyses were used to examine cost dif-
ferences between groups. 
RESULTS: About 63% of patients died in institutions,
while 31% died at home. PCa was the reported cause of
death in 32.8% of cases. After controlling for time pe-
riod, location and cause of death, total medical costs
were lower in the last 3 months of life for PCa patients
who died at home ($1975 versus $3179, p  0.05). No
statistical differences were found in the preceding three
quarters. 
CONCLUSIONS: Total medical costs in the last 3
months of life were lower for PCa patients who die at
home when compared with those dying in healthcare in-
stitutions. Inpatient care costs were nearly three times
higher for patients dying in healthcare institutions. These
cost savings may inform the way we meet the challenge
to improve the quality of life, but also the quality of
death among PCa patients at the end-of-life.
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